7LHB
Crystal structure of Bcl-2 in complex with prodrug ABBV-167
Summary for 7LHB
Entry DOI | 10.2210/pdb7lhb/pdb |
Descriptor | Apoptosis regulator Bcl-2, Phosphoric acid mono-[5-(5-{4-[2-(4-chloro-phenyl)-4,4-dimethyl-cyclohex-1-enylmethyl]-piperazin-1-yl}-2-{3-nitro-4-[(tetrahydro-pyran-4-ylmethyl)-amino]-benzenesulfonylaminocarbonyl}-phenoxy)-pyrrolo[2,3-b]pyridin-7-ylmethyl] ester (3 entities in total) |
Functional Keywords | bcl-2, apoptosis, prodrug, abbv-167 |
Biological source | Homo sapiens (Human) More |
Total number of polymer chains | 3 |
Total formula weight | 61002.08 |
Authors | Judge, R.A.,Salem, A.H. (deposition date: 2021-01-21, release date: 2021-04-14, Last modification date: 2023-10-18) |
Primary citation | Salem, A.H.,Tao, Z.F.,Bueno, O.F.,Chen, J.,Chen, S.,Edalji, R.,Elmore, S.W.,Fournier, K.M.,Harper, K.C.,Hong, R.,Jenkins, G.J.,Ji, J.,Judge, R.A.,Kalvass, J.C.,Klix, R.C.,Ku, Y.Y.,Leverson, J.D.,Marks, R.A.,Marsh, K.C.,Menon, R.M.,Park, C.H.,Phillips, D.C.,Pu, Y.M.,Rosenberg, S.H.,Sanzgiri, Y.D.,Sheikh, A.Y.,Shi, Y.,Stolarik, D.,Suleiman, A.A.,Wang, X.,Zhang, G.G.Z.,Catron, N.D.,Souers, A.J. Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers. Mol.Cancer Ther., 20:999-1008, 2021 Cited by PubMed Abstract: Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other blood-related cancers. Reflecting the large and hydrophobic BH3-binding groove within BCL-2, venetoclax has significantly higher molecular weight and lipophilicity than most orally administered drugs, along with negligible water solubility. Although a technology-enabled formulation successfully achieves oral absorption in humans, venetoclax tablets have limited drug loading and therefore can present a substantial pill burden for patients in high-dose indications. We therefore generated a phosphate prodrug (, ABBV-167) that confers significantly increased water solubility to venetoclax and, upon oral administration to healthy volunteers either as a solution or high drug-load immediate release tablet, extensively converts to the parent drug. Additionally, ABBV-167 demonstrated a lower food effect with respect to venetoclax tablets. These data indicate that beyond-rule-of-5 molecules can be successfully delivered to humans via a solubility-enhancing prodrug moiety to afford robust exposures of the parent drug following oral dosing. PubMed: 33785651DOI: 10.1158/1535-7163.MCT-21-0077 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.068 Å) |
Structure validation
Download full validation report